Head-to-head · WeighScore
Direct Meds vs Fitstry
By GLP-1 ScorecardUpdated
Score comparison
Direct Meds has the higher recorded score — 77.6/100 to 61.5/100.
Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Direct Meds prices compounded injections and sublingual bottles separately; compare the renewal charge and early cancellation cutoff before choosing a plan.
Before you choose
Before comparing the headline prices, the Direct Meds review and the Fitstry review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Direct Meds vs June Health and Edessa vs Fitstry compare each of them with another graded program, and the list of alternatives to Direct Meds ranks the programs closest to Direct Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Direct Meds | Fitstry |
|---|---|---|
| WeighScore | 77.6/100 | 61.5/100 |
| Grade | C+ | C |
| Site position | #33 | #316 |
| Semaglutide | $249/30 days sublingual · $297/mo injectable | $249/mo month-to-month, billed every 4 weeks (cards say starting at $149; compounded) |
| Tirzepatide | $299/30 days sublingual · $399/mo injectable | $339/mo month-to-month, billed every 4 weeks (cards say starting at $199; compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #33 · C+
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Strengths
- Injection and sublingual preparations have separately published prices
- Pricing page advertises medication, evaluation, supplies, shipping and nurse access
- Both semaglutide and tirzepatide are listed
- Checked semaglutide campaign states $147 initially, then $297 monthly
What to consider
- Compounded preparations are not FDA-approved products or assumed equivalent across routes
- No-subscription FAQ wording conflicts with the agreement's 30-day recurring charges
- Renewal cancellation requires 48-hour notice; initial-order cancellation has a separate conditional 24-hour window
- Assigned prescribing practice, dispensing pharmacy and selected longer-plan total need confirmation
- Checked campaign excludes Mississippi and Louisiana; confirm state eligibility
Strengths
- Published pricing before you commit — compounded semaglutide $249/mo and tirzepatide $339/mo month-to-month, with cards starting at $149 and $199
- Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
- Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
- Runs under Weightstry, LLC, a LegitScript-certified practice, with a named support email and phone
- Full compounded lineup — weekly injection, daily oral tablet and microdosing options
What to consider
- The 'starting at' card prices ($149 and $199) are not tied to a stated plan; month-to-month is $249 and $339, billed every 4 weeks
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
- Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Featured provider
Direct Meds
Direct Meds scores 77.6/100 (C+). Direct Meds prices compounded injections and sublingual bottles separately; compare the renewal charge and early cancellation cutoff before choosing a plan.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.